Kooij KL, Koster DIj, Eeltink E, Luijendijk M, Drost L, et al
J Alzheimers Dis (2012) 28:19.10.3233/JAD-2011-111034 45 SchneiderJAArvanitakisZBangWBennettDA
Alongside the anticipated CV safety of many of these agents, evidence for certain sodiumglucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revealed potential cardioprotective effects in patients with T2D who are at high risk of CVD events
Certain individuals notice enhanced libido or more defined ovulation patterns within a couple of weeks, while others require multiple months before observing a quantifiable difference
As a result of the chronic nature and high prevalence of T2D, this condition is associated with a high burden on healthcare systems [2]
[DOI] [PubMed] [Google Scholar] 102.Konosic S., Petricevic M., Ivancan V., Konosic L., Goluza E., Krtalic B., Drmic D., Stupnisek M., Seiwerth S., Sikiric P